PET imaging in patients with meningioma-report of the RANO/PET Group

Norbert Galldiks, Nathalie L Albert, Michael Sommerauer, Anca L Grosu, Ute Ganswindt, Ian Law, Matthias Preusser, Emilie Le Rhun, Michael A Vogelbaum, Gelareh Zadeh, Frédéric Dhermain, Michael Weller, Karl-Josef Langen, Jörg C Tonn

146 Citationer (Scopus)


Meningiomas are the most frequent nonglial primary brain tumors and represent about 30% of brain tumors. Usually, diagnosis and treatment planning are based on neuroimaging using mainly MRI or, rarely, CT. Most common treatment options are neurosurgical resection and radiotherapy (eg, radiosurgery, external fractionated radiotherapy). For follow-up after treatment, a structural imaging technique such as MRI or CT is used. However, these structural imaging modalities have limitations, particularly in terms of tumor delineation as well as diagnosis of posttherapeutic reactive changes. Molecular imaging techniques such as PET can characterize specific metabolic and cellular features which may provide clinically relevant information beyond that obtained from structural MR or CT imaging alone. Currently, the use of PET in meningioma patients is steadily increasing. In the present article, we provide recommendations for the use of PET imaging in the clinical management of meningiomas based on evidence generated from studies being validated by histology or clinical course.

Udgave nummer12
Sider (fra-til)1576-1587
Antal sider12
StatusUdgivet - 29 nov. 2017


Dyk ned i forskningsemnerne om 'PET imaging in patients with meningioma-report of the RANO/PET Group'. Sammen danner de et unikt fingeraftryk.